33.01

2.13% 0.69

Crinetics Pharmaceuticals Inc (CRNX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CRNX? Forum Prognose

Schlusskurs vom Vortag:

$32.32

Offen:

$32.8

24-Stunden-Volumen:

496.61K

Relative Volume:

0.52

Marktkapitalisierung:

$2.86B

Einnahmen:

$4.72M

Nettoeinkommen (Verlust:

$-277.91M

KGV:

-8.8499

EPS:

-3.73

Netto-Cashflow:

$-203.56M

1W Leistung:

+8.19%

1M Leistung:

+8.16%

6M Leistung:

-43.93%

1J Leistung:

-27.99%

1-Tages-Spanne:

$32.49

$33.32

1-Wochen-Bereich:

$30.14

$33.32

52-Wochen-Spanne:

$24.10

$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Firmenname

Crinetics Pharmaceuticals Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (667)

Telefon

858-450-6464

Adresse

6055 LUSK BLVD., SAN DIEGO, CA

Mitarbeiter

437

Twitter

@Crinetics

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

CRNX's Discussions on Twitter

Vergleichen Sie CRNX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRNX Crinetics Pharmaceuticals Inc	33.01	2.86B	4.72M	-277.91M	-203.56M	-3.73
VRTX Vertex Pharmaceuticals Inc	450.50	113.52B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	493.22	52.93B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	300.83	39.71B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	585.93	35.00B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	255.86	26.57B	3.81B	-644.79M	-669.77M	-6.24

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-25	Eingeleitet	Stifel	Buy
2025-02-11	Eingeleitet	TD Cowen	Buy
2025-02-04	Eingeleitet	Wolfe Research	Peer Perform
2025-01-22	Hochstufung	Jefferies	Hold → Buy
2024-03-06	Eingeleitet	Citigroup	Buy
2024-01-16	Eingeleitet	Morgan Stanley	Overweight
2023-12-21	Eingeleitet	Jefferies	Hold
2023-11-20	Fortgesetzt	JP Morgan	Overweight
2023-10-24	Fortgesetzt	Cantor Fitzgerald	Overweight
2023-08-31	Eingeleitet	Oppenheimer	Outperform
2023-04-24	Eingeleitet	Piper Sandler	Overweight
2023-03-30	Eingeleitet	Robert W. Baird	Outperform
2021-11-30	Eingeleitet	JMP Securities	Mkt Outperform
2021-11-23	Eingeleitet	Evercore ISI	Outperform
2021-06-18	Hochstufung	JP Morgan	Neutral → Overweight
2019-12-23	Eingeleitet	ROTH Capital	Buy
2019-02-14	Eingeleitet	H.C. Wainwright	Buy
2018-08-13	Eingeleitet	JP Morgan	Neutral
2018-08-13	Eingeleitet	Leerink Partners	Outperform
2018-08-13	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten

Jun 05, 2025

(CRNX) Trading Report - news.stocktradersdaily.com

Jun 05, 2025

Two Sigma Advisers LP Sells 14,300 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Jun 05, 2025

Jun 02, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 02, 2025

Jun 01, 2025

Jane Street Group LLC Sells 122,188 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Jun 01, 2025

May 31, 2025

Thinking Of Buying Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Stock? Here Is What You Should Know - Stocksregister

May 31, 2025

May 30, 2025

H.C. Wainwright maintains Crinetics stock Buy rating, $81 target By Investing.com - Investing.com Canada

May 30, 2025

H.C. Wainwright maintains Crinetics stock Buy rating, $81 target - Investing.com India

May 30, 2025

May 26, 2025

(CRNX) Investment Report - news.stocktradersdaily.com

May 26, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lessened by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025

May 23, 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 | CRNX Stock News - GuruFocus

May 23, 2025

Crinetics Management Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan

May 23, 2025

Bank of America Corp DE Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

May 23, 2025

BNP Paribas Financial Markets Cuts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

May 23, 2025

May 22, 2025

Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com

May 22, 2025

Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation? - Yahoo Finance

May 22, 2025

May 15, 2025

CRNX Achieves FDA Orphan Drug Status for Paltusotine in Carcinoi - GuruFocus

May 15, 2025

Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? - MSN

May 15, 2025

Crinetics Pharmaceuticals Reports Positive Results for Paltusotine in Treating Surgically Naïve Acromegaly Patients at AACE 2025 - Nasdaq

May 15, 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 - The Manila Times

May 15, 2025

New Clinical Data: Oral Drug Paltusotine Could Replace Injectable Acromegaly TreatmentsKey AACE 2025 Findings - Stock Titan

May 15, 2025

Analysts Set Expectations for CRNX FY2025 Earnings - Defense World

May 15, 2025

May 12, 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 12, 2025

May 10, 2025

Crinetics Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 10, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 09, 2025